HS Icon Blood, antisera, vaccines, toxins and cultures

3002 (Harmonized System 1992 for 4-digit)

Overview This page contains the latest trade data of Blood, antisera, vaccines, toxins and cultures. In 2019, Blood, antisera, vaccines, toxins and cultures were the world's 12th most traded product, with a total trade of $207B. Between 2018 and 2019 the exports of Blood, antisera, vaccines, toxins and cultures grew by 7.74%, from $192B to $207B. Trade in Blood, antisera, vaccines, toxins and cultures represent 1.14% of total world trade.

Exports In 2019 the top exporters of Blood, antisera, vaccines, toxins and cultures  were Switzerland ($32.9B), Ireland ($32.6B), Germany ($29.8B), United States ($29.7B), and Belgium ($20.3B).

Imports In 2019 the top importers of Blood, antisera, vaccines, toxins and cultures were United States ($45.8B), Germany ($21.1B), Belgium ($16.5B), Netherlands ($10.9B), and Switzerland ($9.99B).

Tariffs In 2018 the average tariff for Blood, antisera, vaccines, toxins and cultures was 1.87%, making it the 1247th lowest tariff using the HS4 product classification.

The countries with the highest import tariffs for Blood, antisera, vaccines, toxins and cultures are Iran (20%), Pakistan (8.69%), India (8.18%), Romania (6.86%), and Ethiopia (6.6%). The countries with the lowest tariffs are Angola (0%), Cote d'Ivoire (0%), Egypt (0%), Ghana (0%), and Guinea (0%).

Ranking Blood, antisera, vaccines, toxins and cultures ranks 99th in the Product Complexity Index (PCI).

Description Human blood is used to provide oxygen and nutrients to the tissues and to carry away waste products from the tissues. Animal blood prepared for therapeutic, prophylactic or diagnostic uses is used to study blood-borne diseases and to provide antibodies that are used in the diagnosis of diseases. Antisera and other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, are used in the diagnosis of diseases. Vaccines, toxins, cultures of micro-organisms (excl. yeasts) and similar products are used in the prevention and treatment of diseases.

Historical Data

#permalink to section

Exporters and Importers

#permalink to section

Trade By Country

Top Origin (2019): Switzerland, $32.9B

Top Destination (2019): United States, $45.8B

Blood, antisera, vaccines, toxins and cultures are the world's 12th most traded product.

In 2019, the top exporters of Blood, antisera, vaccines, toxins and cultures were Switzerland ($32.9B), Ireland ($32.6B), Germany ($29.8B), United States ($29.7B), and Belgium ($20.3B).

In 2019, the top importers of Blood, antisera, vaccines, toxins and cultures were United States ($45.8B), Germany ($21.1B), Belgium ($16.5B), Netherlands ($10.9B), and Switzerland ($9.99B).

Explore Visualizations

Market Dynamics

#permalink to section

Trade by country

Value

Top Origin Growth (2018 -  2019): Switzerland, $4.93B

Top Destination Growth (2018 - 2019): United States, $6.78B

Between 2018 and 2019, the exports of Blood, antisera, vaccines, toxins and cultures grew the fastest in Switzerland ($4.93B), Belgium ($4.15B), United States ($2.51B), France ($1.29B), and Austria ($1.04B).

Between 2018 and 2019, the fastest growing importers of Blood, antisera, vaccines, toxins and cultures were United States ($6.78B), China ($2.58B), Germany ($1.91B), Russia ($1.05B), and Japan ($702M).

Explore Visualizations

Market Concentration

#permalink to section

Cumulative market share

Value

This chart shows the evolution of the market concentration of exports of Blood, antisera, vaccines, toxins and cultures.

In 2019,  market concentration measured using Shannon Entropy, was 3.72. This means that most of the exports of Blood, antisera, vaccines, toxins and cultures are explained by 13 countries.

Explore Visualizations

TOP NET EXPORTER (2019): Ireland, $29.4B

TOP NET IMPORTER (2019): United States, $16.1B

This map shows which countries export or import more of Blood, antisera, vaccines, toxins and cultures. Each country is colored based on the difference in exports and imports of Blood, antisera, vaccines, toxins and cultures during 2019.

In 2019, the countries that had a largest trade value in exports than in imports of Blood, antisera, vaccines, toxins and cultures were Ireland ($29.4B), Switzerland ($22.9B), Germany ($8.73B), Belgium ($3.79B), and Singapore ($2.7B).

In 2019, the countries that had a largest trade value in imports than in exports of Blood, antisera, vaccines, toxins and cultures were United States ($16.1B), China ($8.01B), Japan ($5.31B), Canada ($4.19B), and Brazil ($2.95B).

Disaggregation

#permalink to section
Value

In 2019, the world most traded Blood, antisera, vaccines, toxins and cultures, disaggragated by their HS6 level were Blood, toxins, cultures, medical use, nes ($169B), Vaccines, human use ($32.7B), Vaccines, veterinary use, except foot and... ($4B), and Antisera and other blood fractions ($1.27B)

Import Tariffs

#permalink to section

In 2018, the average tariff for importing Blood, antisera, vaccines, toxins and cultures was 1.87%. The countries with the highest tariffs for importing Blood, antisera, vaccines, toxins and cultures were Iran (20%), Pakistan (8.69%), India (8.18%), Romania (6.86%), and Ethiopia (6.6%).

Product Complexity

#permalink to section

Diversification Frontier

#permalink to section
Specialization

The Complexity-Relatedness diagram compares the risk and the strategic value of a product's potential export opportunities. Relatedness is predictive of the probability that a country increases its exports in a product. Complexity, is associated with higher levels of income, economic growth potential, lower income inequality, and lower emissions.

Country by Relatedness

#permalink to section

The following visualization shows the relatedness of Blood, antisera, vaccines, toxins and cultures to countries. Higher relatedness values ​​indicate greater knowledge, which predicts a greater probability of exporting that product in the future.